Therapeutic effects of β-adrenergic antagonists are generally explained by their capacity to block β-adrenoceptors (β-ARs), and β1-AR blockage has become the chosen therapy in the treatment of congestive heart failure [63]. This evidence concerns the gene CTBP1 and congestive heart failure.